MMP9 and neoplasm: Oxalomalic acid can modulate the targeting of IDH1 because it is a competitive inhibitor of IDH by a mechanism that regulates intracellular reactive oxygen species through IDH inactivation, and thus inhibits tumor cell migration by downregulating matrix metalloproteinase-9 [22, 23].